SB86
To Amend The Prohibition On Nonprofit, Tax Exempt, Or Governmentally Funded Hospitals From Holding A Licensed Pharmacy Permit For The Sale At Retail Of Drugs.
Last Action (Jan. 21, 2025): Sine Die adjournment
Sponsors
AI-Generated Summary
Senate Bill 86 amends Arkansas law regarding retail pharmacy permits for hospitals and introduces new anti-competitive restrictions for pharmacy contracting. The bill allows qualifying hospitals to hold retail pharmacy permits, provided they meet specific criteria, such as a minimum daily inpatient census of 24 patients and a location on or near the hospital campus. It prohibits hospitals from obtaining a retail permit if a 24/7 retail pharmacy already exists within 250 yards of the campus. Additionally, the bill establishes strict regulations against anti-competitive pharmacy practices, prohibiting parent entities from using financial incentives to steer patients to specific pharmacies or using reimbursement structures that unfairly favor affiliated pharmacies. The Arkansas State Board of Pharmacy is granted authority to investigate complaints and can terminate the pharmacy permits of entities found in violation. These violations are also designated as breaches of the state's Unfair Practices Act.
Potential Impact Analysis
Who Might Benefit?
Independent pharmacies and smaller retail pharmacy chains stand to benefit from the increased oversight and anti-competitive protections, which limit the ability of large, integrated hospital systems and parent entities to leverage financial incentives or exclusive networks to monopolize local markets. Patients may also benefit from increased pharmacy choice and the prevention of steering tactics that might otherwise restrict where they can obtain medications.
Who Might Suffer?
Large nonprofit or governmentally funded hospital systems are negatively impacted by the new restrictions on obtaining retail pharmacy permits, which limit their expansion based on census requirements and the presence of existing nearby competition. Additionally, parent entities or healthcare organizations that utilize internal pharmacy networks, steering incentives, or specific reimbursement structures to optimize their operations may face significant regulatory challenges and the risk of permit termination under the new anti-competitive contracting prohibitions.
Get Notified
Receive an email when this bill's status changes.